S&P 500   3,776.79 (-0.49%)
DOW   30,895.59 (-0.31%)
QQQ   312.40 (-0.62%)
AAPL   127.90 (-0.78%)
MSFT   213.76 (+0.35%)
FB   251.52 (+2.39%)
GOOGL   1,740.72 (+0.57%)
AMZN   3,104.26 (-0.74%)
TSLA   825.69 (-2.29%)
NVDA   517.82 (-1.93%)
BABA   242.72 (-0.11%)
CGC   33.37 (-3.61%)
GE   11.40 (-2.23%)
MU   81.26 (-0.05%)
AMD   89.18 (-1.77%)
T   29.22 (-0.24%)
NIO   56.14 (-7.77%)
F   9.93 (-2.36%)
ACB   11.93 (-0.25%)
BA   205.18 (-2.25%)
DIS   171.44 (-1.15%)
NFLX   499.87 (-0.20%)
GILD   63.35 (+1.52%)
S&P 500   3,776.79 (-0.49%)
DOW   30,895.59 (-0.31%)
QQQ   312.40 (-0.62%)
AAPL   127.90 (-0.78%)
MSFT   213.76 (+0.35%)
FB   251.52 (+2.39%)
GOOGL   1,740.72 (+0.57%)
AMZN   3,104.26 (-0.74%)
TSLA   825.69 (-2.29%)
NVDA   517.82 (-1.93%)
BABA   242.72 (-0.11%)
CGC   33.37 (-3.61%)
GE   11.40 (-2.23%)
MU   81.26 (-0.05%)
AMD   89.18 (-1.77%)
T   29.22 (-0.24%)
NIO   56.14 (-7.77%)
F   9.93 (-2.36%)
ACB   11.93 (-0.25%)
BA   205.18 (-2.25%)
DIS   171.44 (-1.15%)
NFLX   499.87 (-0.20%)
GILD   63.35 (+1.52%)
S&P 500   3,776.79 (-0.49%)
DOW   30,895.59 (-0.31%)
QQQ   312.40 (-0.62%)
AAPL   127.90 (-0.78%)
MSFT   213.76 (+0.35%)
FB   251.52 (+2.39%)
GOOGL   1,740.72 (+0.57%)
AMZN   3,104.26 (-0.74%)
TSLA   825.69 (-2.29%)
NVDA   517.82 (-1.93%)
BABA   242.72 (-0.11%)
CGC   33.37 (-3.61%)
GE   11.40 (-2.23%)
MU   81.26 (-0.05%)
AMD   89.18 (-1.77%)
T   29.22 (-0.24%)
NIO   56.14 (-7.77%)
F   9.93 (-2.36%)
ACB   11.93 (-0.25%)
BA   205.18 (-2.25%)
DIS   171.44 (-1.15%)
NFLX   499.87 (-0.20%)
GILD   63.35 (+1.52%)
S&P 500   3,776.79 (-0.49%)
DOW   30,895.59 (-0.31%)
QQQ   312.40 (-0.62%)
AAPL   127.90 (-0.78%)
MSFT   213.76 (+0.35%)
FB   251.52 (+2.39%)
GOOGL   1,740.72 (+0.57%)
AMZN   3,104.26 (-0.74%)
TSLA   825.69 (-2.29%)
NVDA   517.82 (-1.93%)
BABA   242.72 (-0.11%)
CGC   33.37 (-3.61%)
GE   11.40 (-2.23%)
MU   81.26 (-0.05%)
AMD   89.18 (-1.77%)
T   29.22 (-0.24%)
NIO   56.14 (-7.77%)
F   9.93 (-2.36%)
ACB   11.93 (-0.25%)
BA   205.18 (-2.25%)
DIS   171.44 (-1.15%)
NFLX   499.87 (-0.20%)
GILD   63.35 (+1.52%)
Log in
EPA:GNFT

Genfit SA (GNFT.PA) Stock Forecast, Price & News

€4.48
0.00 (0.00 %)
(As of 01/14/2021 12:00 AM ET)
Add
Compare
Today's Range
€4.37
Now: €4.48▼
€4.62
50-Day Range
€3.96
MA: €4.27▼
€4.73
52-Week Range N/A
Volume619,148 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, autoimmune, and fibrotic diseases affecting primarily the liver and gastroenterology. The company's lead products include Elafibranor, which is in pivotal Phase III clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as completed Phase II clinical trial to treat patients with primary biliary cholangitis; and Nitazoxanide that is in Phase II proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis. It is also developing in-vitro diagnostic tests for the identification of patients with NASH; NIS4 for identifying patients with NASH and fibrosis; and TGFTX1 preclinical program for treating psoriasis or respiratory conditions, such as neutrophilic asthma, chronic obstructive pulmonary disease (COPD), and the asthma-COPD overlap syndrome. Genfit SA was founded in 1999 and is headquartered in Loos, France.

MarketRank™

Overall MarketRank™

0.54 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Stock Exchange EPA
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolEPA:GNFT
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.genfit.com
Phone33 3 20 16 40 00
EmployeesN/A

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Outstanding SharesN/A
Market CapN/A
Next Earnings DateN/A
OptionableNot Optionable
€4.48
0.00 (0.00 %)
(As of 01/14/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GNFT News and Ratings via Email

Sign-up to receive the latest news and ratings for GNFT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Genfit SA (GNFT.PA) (EPA:GNFT) Frequently Asked Questions

How has Genfit SA (GNFT.PA)'s stock price been impacted by COVID-19?

Genfit SA (GNFT.PA)'s stock was trading at €12.78 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, GNFT shares have decreased by 64.9% and is now trading at €4.48.
View which stocks have been most impacted by COVID-19.

What stocks does MarketBeat like better than Genfit SA (GNFT.PA)?

Wall Street analysts have given Genfit SA (GNFT.PA) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Genfit SA (GNFT.PA) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are some of Genfit SA (GNFT.PA)'s key competitors?

Some companies that are related to Genfit SA (GNFT.PA) include (CHV) (CHV), (DDXS) (DDXS), (PREV) (PREV), (TNGN) (TNGN), 138267 (COM.TO) (COM), 17031 (MYM), Abattis Bioceuticals (ATTBF), Abzena plc (ABZA.L) (ABZA), Acrux Limited (ACR.AX) (ACR), Actinogen Medical Limited (ACW.AX) (ACW), AdAlta Limited (1AD.AX) (1AD), ADiTx Therapeutics (ADTX), Admedus (AHZ), Alaric (HALB) and Algernon Pharmaceuticals (AGNPF).
View all of GNFT's competitors.

What other stocks do shareholders of Genfit SA (GNFT.PA) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Genfit SA (GNFT.PA) investors own include Alimentation Couche-Tard (ATD.B), Aecon Group Inc. (ARE.TO) (ARE), Algonquin Power & Utilities Corp. (AQN.TO) (AQN), Aptiv (APTV), American Tower (AMT), Advanced Micro Devices (AMD), Ambarella (AMBA), Albemarle (ALB), Adobe (ADBE) and Abbott Laboratories (ABT).

Who are Genfit SA (GNFT.PA)'s key executives?

Genfit SA (GNFT.PA)'s management team includes the following people:
  • Mr. Jean-François Mouney, Co-Founder & Chairman (Age 66, Pay $1.4M)
  • Mr. M. Pascal Prigent, Chief Exec. Officer (Age 53, Pay $325.11k)
  • Prof. Bart Staels, Co-Founder & Chairman of the Scientific Advisory Board (Age 58)
  • Ms. Nathalie Huitorel, Exec. VP and Chief Financial & Admin. Officer (Age 60)
  • Dr. Dean W. Hum, Chief Operating Officer (Age 59)
  • Ms. Naomi Eichenbaum, VP of Investor Relations
  • Mr. Laurent Lannoo, Corp. Sec. & Director of Legal Affairs (Age 51)
  • Mr. Jean-Christophe Marcoux, Chief Strategy Officer (Age 44)
  • Dr. Carol L. Addy M.D., Chief Medical Officer (Age 61)
  • Mr. Suneil Hosmane Ph.D., Head of Global Diagnostics (Age 39)

What is Genfit SA (GNFT.PA)'s stock symbol?

Genfit SA (GNFT.PA) trades on the EPA under the ticker symbol "GNFT."

What is Genfit SA (GNFT.PA)'s stock price today?

One share of GNFT stock can currently be purchased for approximately €4.48.

What is Genfit SA (GNFT.PA)'s official website?

The official website for Genfit SA (GNFT.PA) is www.genfit.com.

How can I contact Genfit SA (GNFT.PA)?

The company can be reached via phone at 33 3 20 16 40 00.

This page was last updated on 1/15/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.